Video content is prompted by the following:
PARP Inhibitors in Ovarian Cancer Treatment
Key Themes:
- Biomarker-directed PARP inhibitor use in frontline treatment
- Current FDA approvals and indications
- Overall survival concerns in platinum-sensitive settings
Notable Insights:
- Current frontline approvals:
- Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum
- Olaparib with bevacizumab for HRD-positive tumors
- Niraparib approved for all-comers whose tumors responded to chemotherapy
- Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
- The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.
Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer…transformative in a biomarker selected way” and noted: “Best place to use them is in frontline…there is the chance we are curing more patients. We believe that.”
